851759-19-8

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 6-chloro-2-Methylnicotinate is used as an intermediate in the synthesis of various drugs, contributing to the development of new therapeutic agents.
Used in Neurological and Psychiatric Disorders Treatment:
Methyl 6-chloro-2-Methylnicotinate is used as a potential therapeutic agent for the treatment of neurological and psychiatric disorders, due to its pharmacological properties.
Used in Drug Development:
Methyl 6-chloro-2-Methylnicotinate is used as a valuable candidate for drug development, owing to its antioxidant and anti-inflammatory effects, which can be beneficial in the treatment of various conditions.

InChI:InChI=1/C8H8ClNO2/c1-5-6(8(11)12-2)3-4-7(9)10-5/h3-4H,1-2H3

Upstream product

• 1033809-42-5 methyl 2-methyl-1-oxo-1lambda5-pyridine-3-carboxylate 
• 67-56-1 methanol 
• 137129-98-7 6-chloro-2-methylpyridine-3-carboxylic acid 
• 65719-09-7 methyl 2-methylnicotinate 
• 223788-08-7 methyl 6-hydroxy-2-methylnicotinate 
• 14205-39-1 methyl 3-aminocrotonate 

Downstream Products

• 1227562-32-4 methyl 6-bromo-2-methylnicotinate 

Relevant academic research and scientific papers

A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF

The present invention relates to a class of bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof, and specifically provides a compound of formula (I), or an isotopic compound thereof, or an optical isomer thereof, or a tautomer thereof, or a pharmacologically acceptable salt thereof, or a prodrug thereof, or a solvate thereof, wherein ARB is an androgen receptor recognition/binding part, L is a link part, and U is a ubiquitin protease recognition/binding part; and the three parts are connected by means of chemical bonds. The compound can perform the targeted degradation on androgen receptors in prostate cancer cells, and suppress the proliferation of the prostate cancer cells, and also show good metabolic stability and pharmacokinetic properties. The compound has good application prospect in the preparation of targeted chimeras for protein degradation of androgen receptors and in the preparation of drugs for treating the related diseases regulated by the androgen receptors.

1,7-naphthyridine derivative, preparation method and applications thereof

The present invention relates to a compound represented by a formula (I) or a tautomer, an optical isomer, a nitrogen oxide, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, a preparation method of the compound, a pharmaceutical composi

PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS

The present disclosure provides selective phosphoinositide 3-kinase gamma inhibitors of Formula (I) including (I-a), (I-b), (I-c), and (I-d), or pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of conditions mediated

Halogenated allyl amine type SSAO/VAP-1 inhibitor and application thereof

The invention belongs to the technical field of medicine, and particularly relates to a halogenated allyl amine type compound shown as a formula I, medically acceptable salt, ester or stereo isomers thereof, wherein R1, R2, R3, R4, R5, R6, L1, Cy1, R7 and p are defined in description. The invention also relates to a medicine preparation containing the compounds, a medicine composition containing the compounds, and application of the compounds to prevention and/or treatment on diseases relevant to SSAO/VAP 1 protein or diseases caused by SSAO/VAP 1 protein mediating. The formula I is shown in the description.

DIPHENYL DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

INHIBITORS OF JANUS KINASES

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.